Stifel has initiated coverage on Immunic (IMUX) with a Buy rating and a price target of $2.50, citing its lead candidate, VidoCa, as a promising treatment for multiple sclerosis. The potential for improved safety profiles may help VidoCa capture market share amid existing competitive pressures, with critical data expected by late 2026 and regulatory submission in 2027.
Immunic Inc's announcement of a private placement worth up to $400 million is driving significant interest and a surge in the stock price. This capital infusion may strengthen its financial position as it progresses through late-stage trials, potentially attracting more investor confidence and impacting future valuations.
